152 related articles for article (PubMed ID: 38305000)
1. Respiratory syncytial virus immunoprophylaxis: Novel opportunities and a call for equity.
Rzymski P; Gwenzi W
J Med Virol; 2024 Feb; 96(2):e29453. PubMed ID: 38305000
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing activity of anti-respiratory syncytial virus monoclonal antibody produced in
Pisuttinusart N; Rattanapisit K; Srisaowakarn C; Thitithanyanont A; Strasser R; Shanmugaraj B; Phoolcharoen W
Hum Vaccin Immunother; 2024 Dec; 20(1):2327142. PubMed ID: 38508690
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children.
Nair H; Verma VR; Theodoratou E; Zgaga L; Huda T; Simões EA; Wright PF; Rudan I; Campbell H
BMC Public Health; 2011 Apr; 11 Suppl 3(Suppl 3):S30. PubMed ID: 21501449
[TBL] [Abstract][Full Text] [Related]
4. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
[TBL] [Abstract][Full Text] [Related]
5. The third pandemic: The respiratory syncytial virus landscape and specific considerations for the allergist/immunologist.
Frenkel LD; Gaur S; Bellanti JA
Allergy Asthma Proc; 2023 Jul; 44(4):220-228. PubMed ID: 37236777
[No Abstract] [Full Text] [Related]
6. Advances in RSV vaccine research and development - A global agenda.
Higgins D; Trujillo C; Keech C
Vaccine; 2016 Jun; 34(26):2870-2875. PubMed ID: 27105562
[TBL] [Abstract][Full Text] [Related]
7. WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.
Sparrow E; Adetifa I; Chaiyakunapruk N; Cherian T; Fell DB; Graham BS; Innis B; Kaslow DC; Karron RA; Nair H; Neuzil KM; Saha S; Smith PG; Srikantiah P; Were F; Zar HJ; Feikin D
Vaccine; 2022 Jun; 40(26):3506-3510. PubMed ID: 35184927
[TBL] [Abstract][Full Text] [Related]
8. Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries.
Atwell JE; Lutz CS; Sparrow EG; Feikin DR
Vaccine; 2022 Jul; 40(32):4361-4370. PubMed ID: 35725783
[TBL] [Abstract][Full Text] [Related]
9. Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand.
Prasad N; Read JM; Jewell C; Waite B; Trenholme AA; Huang QS; Grant CC; Newbern EC; Hogan AB
Vaccine; 2021 Jul; 39(31):4383-4390. PubMed ID: 34147296
[TBL] [Abstract][Full Text] [Related]
10. New respiratory syncytial virus immunization products in low- and middle-income countries: potential for cost-effective impact on a high burden of disease in young infants.
Srikantiah P; Klugman KP
BMC Med; 2023 May; 21(1):177. PubMed ID: 37183242
[TBL] [Abstract][Full Text] [Related]
11. Value profile for respiratory syncytial virus vaccines and monoclonal antibodies.
Fleming JA; Baral R; Higgins D; Khan S; Kochar S; Li Y; Ortiz JR; Cherian T; Feikin D; Jit M; Karron RA; Limaye RJ; Marshall C; Munywoki PK; Nair H; Newhouse LC; Nyawanda BO; Pecenka C; Regan K; Srikantiah P; Wittenauer R; Zar HJ; Sparrow E
Vaccine; 2023 Nov; 41 Suppl 2():S7-S40. PubMed ID: 37422378
[TBL] [Abstract][Full Text] [Related]
12. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
13. The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models.
Baral R; Li X; Willem L; Antillon M; Vilajeliu A; Jit M; Beutels P; Pecenka C
Vaccine; 2020 Jul; 38(33):5139-5147. PubMed ID: 32586761
[TBL] [Abstract][Full Text] [Related]
14. Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus.
Hervé PL; Dhelft V; Zuniga A; Ghasparian A; Rassek O; Yim KC; Donne N; Lambert PH; Benhamou PH; Sampson HA; Mondoulet L
Vaccine; 2021 Jul; 39(32):4555-4563. PubMed ID: 34154864
[TBL] [Abstract][Full Text] [Related]
15. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
[TBL] [Abstract][Full Text] [Related]
16. Maternal RSV vaccine development. Where to from here?
Gunatilaka A; Giles ML
Hum Vaccin Immunother; 2021 Nov; 17(11):4542-4548. PubMed ID: 34499565
[TBL] [Abstract][Full Text] [Related]
17. A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats.
Rostad CA; Stobart CC; Gilbert BE; Pickles RJ; Hotard AL; Meng J; Blanco JCG; Moin SM; Graham BS; Piedra PA; Moore ML
J Virol; 2016 Aug; 90(16):7508-7518. PubMed ID: 27279612
[TBL] [Abstract][Full Text] [Related]
18. Parental knowledge about respiratory syncytial virus (RSV) and attitudes to infant immunization with monoclonal antibodies.
Lee Mortensen G; Harrod-Lui K
Expert Rev Vaccines; 2022 Oct; 21(10):1523-1531. PubMed ID: 35929971
[TBL] [Abstract][Full Text] [Related]
19. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
Munoz FM
Curr Opin Infect Dis; 2015 Jun; 28(3):221-4. PubMed ID: 25918956
[TBL] [Abstract][Full Text] [Related]
20. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]